​

GoodRx (GDRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GDRX Stock Forecast

GoodRx (GDRX) stock forecast, based on 20 Wall Street analysts, predicts a 12-month average price target of $14.57, with a high of $45.00 and a low of $3.00. This represents a 224.50% increase from the last price of $4.49.

- $9 $18 $27 $36 $45 High: $45 Avg: $14.57 Low: $3 Last Closed Price: $4.49

GDRX Stock Rating

GoodRx stock's rating consensus is Buy, based on 20 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (60.00%), 8 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 20 0 8 12 Strong Sell Sell Hold Buy Strong Buy

GDRX Price Target Upside V Benchmarks

TypeNameUpside
StockGoodRx224.50%
SectorHealthcare Stocks 35.25%
IndustryHealthcare Information Services Stocks 36.10%

Price Target Trends

1M3M12M
# Anlaysts--4
Avg Price Target--$9.63
Last Closing Price$4.49$4.49$4.49
Upside/Downside--114.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25177-116
Mar, 25277-117
Feb, 25277-117
Jan, 25277-117
Dec, 24277-117
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 10, 2024Craig HettenbachMorgan Stanley$9.50$8.5511.11%111.58%
May 23, 2024Mark MahaneyRBC Capital$10.00$7.2038.89%122.72%
May 16, 2024Stephanie DavisBarclays$9.00$8.0611.66%100.45%
May 16, 2024Aaron KesslerRaymond James$10.00$7.2737.55%122.72%
Apr 10, 2024Scott SchoenhausBOCOM International Holdings Company$9.00$6.9230.06%100.45%
Apr 10, 2024Scott SchoenhausKeyBanc$9.00$6.7433.53%100.45%
Mar 25, 2024Stan BerenshteynWells Fargo$10.00$7.2338.31%122.72%
Nov 13, 2023Eric SheridanGoldman Sachs$3.00$4.73-36.58%-33.18%
Dec 01, 2022Citigroup$7.00$4.3660.55%55.90%
Aug 09, 2022Steve ValiquetteBarclays$13.00$7.7667.53%189.53%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 10, 2025CitigroupBuyBuyhold
Oct 01, 2024Cowen & Co.BuyBuyhold
Aug 16, 2024UBSBuyBuyhold
Aug 09, 2024Raymond JamesOutperformStrong Buyupgrade
Jun 10, 2024Morgan StanleyEqual-WeightEqual-Weighthold
May 23, 2024RBC CapitalSector PerformOutperformupgrade
May 16, 2024BarclaysOverweightOverweighthold
May 16, 2024Wells FargoSector PerformSector Performhold
May 16, 2024KeyBancOverweightOverweighthold
May 16, 2024Raymond JamesStrong BuyOutperformupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.75$-0.06$-0.08$-0.02$0.12----
Avg Forecast$0.36$0.35$0.28$0.28$0.34$0.40$0.48$0.58$0.72
High Forecast$0.37$0.36$0.28$0.31$0.35$0.43$0.68$0.76$0.74
Low Forecast$0.35$0.34$0.27$0.26$0.33$0.39$0.27$0.43$0.71
Surprise %-308.33%-117.14%-128.57%-107.14%-64.71%----

Revenue Forecast

$500M $620M $740M $860M $980M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$550.70M$745.42M$766.55M$750.26M$792.32M----
Avg Forecast$545.10M$749.25M$760.83M$752.87M$793.57M$825.58M$883.98M$963.42M$1.04B
High Forecast$555.40M$763.41M$772.13M$757.12M$793.95M$843.69M$883.99M$963.43M$1.06B
Low Forecast$535.25M$735.71M$753.01M$746.09M$793.15M$813.55M$883.96M$963.42M$1.02B
Surprise %1.03%-0.51%0.75%-0.35%-0.16%----

Net Income Forecast

$-300M $-170M $-40M $90M $220M $350M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-293.62M$-25.25M$-32.83M$-8.87M$46.53M----
Avg Forecast$147.28M$-35.11M$-92.71M$-8.87M$140.71M$167.93M$193.70M$244.37M$295.43M
High Forecast$150.90M$-5.06M$-70.48M$-6.69M$144.80M$176.33M$277.92M$312.25M$303.90M
Low Forecast$143.82M$-65.17M$-114.94M$-11.05M$136.63M$159.53M$109.48M$176.49M$289.88M
Surprise %-299.36%-28.08%-64.59%--66.93%----

GDRX Forecast FAQ

Is GoodRx stock a buy?

GoodRx stock has a consensus rating of Buy, based on 20 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 8 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that GoodRx is a favorable investment for most analysts.

What is GoodRx's price target?

GoodRx's price target, set by 20 Wall Street analysts, averages $14.57 over the next 12 months. The price target range spans from $3 at the low end to $45 at the high end, suggesting a potential 224.50% change from the previous closing price of $4.49.

How does GoodRx stock forecast compare to its benchmarks?

GoodRx's stock forecast shows a 224.50% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the healthcare information services stocks industry (36.10%).

What is the breakdown of analyst ratings for GoodRx over the past three months?

  • April 2025: 6.25% Strong Buy, 43.75% Buy, 43.75% Hold, 0% Sell, 6.25% Strong Sell.
  • March 2025: 11.76% Strong Buy, 41.18% Buy, 41.18% Hold, 0% Sell, 5.88% Strong Sell.
  • February 2025: 11.76% Strong Buy, 41.18% Buy, 41.18% Hold, 0% Sell, 5.88% Strong Sell.

What is GoodRx’s EPS forecast?

GoodRx's average annual EPS forecast for its fiscal year ending in December 2025 is $0.4, marking a 233.33% increase from the reported $0.12 in 2024. Estimates for the following years are $0.48 in 2026, $0.58 in 2027, and $0.72 in 2028.

What is GoodRx’s revenue forecast?

GoodRx's average annual revenue forecast for its fiscal year ending in December 2025 is $825.58M, reflecting a 4.20% increase from the reported $792.32M in 2024. The forecast for 2026 is $883.98M, followed by $963.42M for 2027, and $1.04B for 2028.

What is GoodRx’s net income forecast?

GoodRx's net income forecast for the fiscal year ending in December 2025 stands at $167.93M, representing an 260.91% increase from the reported $46.53M in 2024. Projections indicate $193.7M in 2026, $244.37M in 2027, and $295.43M in 2028.